Author

admin

Browsing

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have…

Errawarra Resources Ltd (ASX: ERW) is pleased to advise that recent surface sampling at its Elizabeth Hill Project has returned multiple elevated portable XRF (pXRF) silver (Ag) readings including high grade results up to 920g/t Ag. HIGHLIGHTS: pXRF surface sampling has returned multiple high-grade silver (Ag) results up to 920g/t…